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The incidence of endometrial cancer has steadily 
increased over the past decade, with 320 000 new 
cases reported worldwide in 2012.1 Endometrial cancer 
is the ﬁ fth most common cancer in women, and 
incidence is projected to increase2 because of an 
increased prevalence of obesity and an ageing 
population. Although most patients present with 
early-stage low-risk disease, a rise in incidence is 
expected to lead to an increasing number of high-risk 
cases at presentation. This heterogenous group of 
tumours is characterised by higher grade and stage, 
deep myometrial invasion, lymph-vascular space 
invasion, or non-endometrioid histologies, such as 
serous or clear-cell cancers. Despite optimum surgical 
treatments, these tumours have an increased risk 
of local and distant recurrences and are therefore 
considered targets for adjuvant therapy. External beam 
radiotherapy showed a signiﬁ cant reduction in the risk 
of local relapse compared with observation, but did 
not show a signiﬁ cant survival advantage in a high-risk 
subgroup meta-analysis.3 
Although endometrial cancers are generally radio-
sensitive and local relapse might be prevented by 
radiotherapy, many patients with high-risk disease 
still have distant metastatic relapses. Therefore, a 
systemic treatment with adjuvant chemotherapy was 
proposed as a solution, with or without radiotherapy. 
Randall and colleagues4 previously randomly 
assigned 396 patients with stage III–IV endometrial 
carcinoma to adjuvant chemotherapy versus whole-
abdominal irradiation and showed a survival beneﬁ t 
for adjuvant chemotherapy. Hogberg and colleagues5 
pooled the data of the NSGO-EC-95016 and the 
MaNGO ILIADE-III trials and reported on 534 patients 
randomly assigned to either radiotherapy or combined 
sequential radiotherapy and chemotherapy in the 
adjuvant setting. The NSGO-EC-9501 study and both 
studies combined showed a signiﬁ cant improvement 
in progression-free and cancer-speciﬁ c survival in the 
combined treatment group.
In The Lancet Oncology, Stephanie de Boer and 
colleagues7 report the ﬁ rst results of the multicentre 
PORTEC-3 randomised trial, focusing on toxicity and 
2-year quality in those who received radiotherapy and 
those who received chemotherapy plus radiotherapy. 
Overall, 686 women were randomly assigned (330 to 
receive chemotherapy plus radiotherapy and 330 to 
receive radiotherapy alone). Baseline characteristics in 
both groups were well balanced, although comorbidity 
rates were higher in the combined therapy group. 
Toxicity and quality of life data were available for 
660 patients and showed a higher incidence of severe 
adverse events and patient-reported symptoms 
in the combined group with radiotherapy and 
chemotherapy, mainly related to the well known 
side-eﬀ ects of paclitaxel and carboplatin therapy. 
Most patients with adverse events recovered quickly 
after the end of the treatment, although peripheral 
sensory neuropathy was deemed troublesome by 
a quarter of all patients in the combined group 
at 2 years. Although the toxicities of combined 
treatment were shown to be manageable, whether 
this investment of adding chemotherapy will be 
rewarded by an improved outcome in the long term 
remains unclear. The fact that a toxicity and quality 
of life analysis were included as secondary endpoints 
in the trial design, which was not the case for the 
combined NSGO-EC-9501 and MaNGO ILIADE-III 
trials,5 is a merit to the researchers. However, the 
trial had a few limitations. More than a third of all 
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A central question in oncology refers to the optimum 
timing of treatment initiation in asymptomatic 
patients with a malignant phenotype. Early treatment 
initiation did not improve survival in studies of chronic 
lymphocytic leukaemia1 and asymptomatic low-grade 
non-Hodgkin lymphoma,2,3 but this outcome might 
change with the use of novel drugs. In smouldering 
multiple myeloma—a precursor state of active 
myeloma—several attempts to improve patient 
outcomes remained futile,4 for two main reasons. 
First, the prognosis of patients with smouldering 
myeloma is very heterogeneous, with some patients 
progressing to multiple myeloma rapidly and others 
only after long-term follow-up or even not at all. 
Second, before the introduction of novel drugs, the 
eﬃ  cacy of available treatment was suboptimum at best; 
Early treatment for high-risk smouldering myeloma: 
has the time come?
patients in both groups did not receive a complete 
staging surgery, including lymphadenectomy, because 
lymphadenectomy was optional. This could lead to 
the underestimation of stage IIIC disease in which 
the addition of chemotherapy has been shown to 
increase survival.4,5 Although two large randomised 
trials8,9 could not establish the value of a systematic 
lymphadenectomy in stage I endometrial cancer, the 
number of high-risk cases in these studies was rather 
small. To establish the value of a pelvic and para-aortic 
lymphadenectomy in high-risk endometrial cancer, 
the STATEC study (Selective Targeting of Adjuvant 
Therapy for Endometrial Cancer, NCT02566811) 
is in preparation at present. Furthermore, if future 
results of the PORTEC-3 trial conﬁ rm the progression-
free and cancer-speciﬁ c survival beneﬁ t for the 
combined treatment group observed in the combined 
NSGO-EC-9501 and MaNGO ILIADE-III trials, the 
question remains of how much radiotherapy adds 
to the observed eﬀ ect of adjuvant chemotherapy. 
This will be addressed by the results of the ongoing 
GOG-258 trial (NCT00942357), studying the 
same combined chemoradiotherapy regimen as in 
PORTEC-3.
Overall, the study by de Boer and colleagues 
clearly shows the feasibility of combined modality 
therapy for high-risk endometrial cancer. If the 
study shows a survival beneﬁ t for the adjuvant 
chemotherapy plus radiotherapy, combined therapy 
is expected to become the standard-of-care for 
high-risk endometrial cancer. With the present 
data on toxicity and quality of life, the (yet to be 
determined) survival beneﬁ ts of chemotherapy can be 
weighed against the adverse events and quality of life 
measures reported in this study, which will improve 
the adjuvant therapy for women with high-risk 
endometrial cancer.
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